Sarfaraz Sidra, Hayes Robert C, Hunt Anne-Marie
Faculty of Medicine, Dalhousie University, Halifax, NS, Canada.
Division of Clinical Dermatology & Cutaneous Science, Dalhousie Medicine New Brunswick, Saint John, NB, Canada.
SAGE Open Med Case Rep. 2023 Mar 30;11:2050313X231164248. doi: 10.1177/2050313X231164248. eCollection 2023.
Advanced basal cell carcinoma may be treated with systemic therapies such as hedgehog pathway inhibitors or programmed cell death protein 1 inhibitors, namely cemiplimab. We report a case of a 70-year-old man with a nodulo-infiltrative advanced basal cell carcinoma over the right posterior neck and scapula. The patient had a partial response to the hedgehog pathway inhibitor, vismodegib. The tumour progressed, and the patient was switched from vismodegib to radiotherapy combined with cemiplimab, which led to a significant reduction in pain, bleeding, and tumour size. A combined treatment approach with radiotherapy and cemiplimab may be beneficial for advanced basal cell carcinoma cases that progress after treatment with hedgehog pathway inhibitors.
晚期基底细胞癌可采用全身治疗，如刺猬通路抑制剂或程序性细胞死亡蛋白1抑制剂，即西米普利单抗。我们报告了一例70岁男性患者，其右后颈部和肩胛骨处患有结节浸润性晚期基底细胞癌。该患者对刺猬通路抑制剂维莫德吉有部分反应。肿瘤进展后，患者从维莫德吉改为放疗联合西米普利单抗治疗，这导致疼痛、出血和肿瘤大小显著减轻。对于经刺猬通路抑制剂治疗后进展的晚期基底细胞癌病例，放疗联合西米普利单抗的联合治疗方法可能有益。
